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Levodopa is the most effective medication for motor symptoms in Parkinson’s
disease. However, various motor and non-motor complications are associated with
levodopa treatment, resulting from altered levodopa-dopamine metabolism with disease
progression and long-term use of the drug. The present review emphasizes the role of
monoamine transporters other than the dopamine transporter in uptake of extracellular
dopamine in the dopamine-denervated striatum. When dopaminergic neurons are
lost and dopamine transporters decreased, serotonin and norepinephrine transporters
compensate by increasing uptake of excessive extracellular dopamine in the striatum.
Organic cation transporter-3 and plasma membrane monoamine transporter, low affinity,
and high capacity transporters, also potentially uptake dopamine when high-affinity
transporters do not work normally. Selective serotonin reuptake inhibitors and serotonin
norepinephrine reuptake inhibitors are often administered to patients with Parkinson’s
disease presenting with depression, pain or other non-motor symptoms. Thus, it is
important to address the potential of these drugs to modify dopamine metabolism and
uptake through blockade of the compensatory function of these transporters, which
could lead to changes in motor symptoms of Parkinson’s disease.
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INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disease associated with progressive loss of
nigrostriatal dopaminergic neurons. A patient with PD presents motor symptoms such as tremor,
akinesia, hypokinesia, rigidity, and postural disturbance, and non-motor symptoms such as pain,
sleep disturbance, apathy, depression, and constipation (Jankovic, 2008). Levodopa is the most
Abbreviations: 3-MT, 3-methoxytyramine; 3-OMD, 3-O-methyldopa; 6-OHDA, 6-hydroxydopamine; AADC, aromatic
amino acid decarboxylase; ALD.DH, aldehyde dehydrogenase; COMT, catechol-O-methyltransferase; D-22, decynium-
22; D2R, dopamine D2 receptor; DA, dopamine; DAT, dopamine transporter; DCI, dopa-decarboxylase inhibitor;
DOPAC, dihydroxyphenylacetic acid; DOPALD, dihydroxyphenylacetaldehyde; DR, dopamine receptor; HVA, homovanillic
acid; MAO, monoamine oxidase; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NET, norepinephrine transporter,
noradrenaline transporter; OCT, organic cation transporter; PD, Parkinson’s disease; PMAT, plasma membrane monoamine
transporter; SERT, serotonin transporter; SLC, solute carrier; SNRI, serotonin norepinephrine reuptake inhibitor; SSRI,
selective serotonin reuptake inhibitor; VMAT-2, vesicular monoamine transporter-2.
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effective drug to alleviate motor symptoms of PD (Mercuri
and Bernardi, 2005; Smith et al., 2012); however, levodopa-
induced motor and non-motor complications occur with long-
term use of the drug (Aquino and Fox, 2015; Beaulieu-Boire
and Lang, 2015). Levodopa-induced complications are mainly
due to altered levodopa-dopamine metabolism in the brain and
the narrowing of the therapeutic window in patients with PD
(Olanow and Obeso, 2000; Pavese et al., 2006). Striatal function
targeted by levodopa is deeply involved with levodopa-associated
motor complications such as wearing-off and levodopa-induced
dyskinesia (de la Fuente-Fernández et al., 2004). Detailed
mechanisms of levodopa-dopamine metabolism in the striatum
of patients with PD are far from evident yet, however, a number
of studies have shed light on this issue using animal models of PD
and human subjects.
In the peripheral system (Figure 1), levodopa administered
systemically, whether oral or intravenous, undergoes
decarboxylation by aromatic amino acid decarboxylase (AADC)
and is converted to dopamine. Peripheral dopamine cannot
cross the blood-brain barrier and enter the brain (Nutt et al.,
1985; Cedarbaum, 1987). Some administered levodopa is
O-methylated by catechol-O-methyltransferase (COMT) and
converted to 3-O-methyldopa (3-OMD), which does not work
as a dopaminergic neurotransmitter in the striatum (Kaakkola,
2000). The remaining levodopa can cross the blood-brain barrier
and reach the central nervous system. In the normal striatum,
FIGURE 1 | Schematic diagram showing metabolism and uptake of levodopa-derived dopamine. Levodopa therapy is usually combined with a
dopa-decarboxylase inhibitor (carbidopa or benserazide) in order to minimize peripheral conversion of levodopa. 3-MT, 3-methoxytyramine; 3-OMD, 3-O-methyldopa;
AADC, aromatic amino acid decarboxylase; ALD.DH, aldehyde dehydrogenase; BBB, blood–brain barrier; COMT, catechol-O-methyltransferase; DAT, dopamine
transporter; DCI, dopa-decarboxylase inhibitor; DOPAC, dihydroxyphenylacetic acid; HVA, homovanillic acid; MAO, monoamine oxidase; NET, norepinephrine
transporter, noradrenaline transporter; OCT-3, organic cation transporter-3; PMAT, plasma membrane monoamine transporter; SERT, serotonin transporter.
levodopa is metabolized, released, and reuptaken mainly by
dopaminergic neurons. Dopaminergic neurons convert levodopa
into dopamine by AADC, and store dopamine in the synaptic
vesicles by vesicular monoamine transporter-2 (VMAT-2;
Wimalasena, 2011), and release dopamine to the synaptic cleft.
Dopamine transporters (DAT) are expressed at terminals of
dopaminergic neurons (Nirenberg et al., 1996) and reuptake
extracellular dopamine for reuse or metabolization (Cass et al.,
1993; Cass and Gerhardt, 1994; Giros et al., 1996; Jaber et al.,
1997; Mundorf et al., 2001; Rice et al., 2011). With DAT and
negative feedback by D2 dopamine receptors (Rice et al.,
2011), dopaminergic neurons can control the concentration of
extracellular dopamine levels (Figure 2A).
When dopaminergic neurons projecting to the striatum
are markedly decreased in PD, serotonergic neurons play a
significant role in converting exogenous levodopa into dopamine,
storing dopamine, and releasing dopamine into synapses in
the striatum (Ng et al., 1970, 1971; Hollister et al., 1979; Arai
et al., 1994, 1995, 1996; Tanaka et al., 1999; Kannari et al.,
2001; Maeda et al., 2003, 2005; Politis et al., 2010; Cheshire
and Williams, 2012; Politis et al., 2014; Figure 2B). However,
serotonergic neurons do not have dopamine D2 receptors; the
absence of negative feedback allows uncontrolled synthesis and
release of dopamine from serotonergic neurons. Furthermore,
because serotonergic neurons do not express DAT, they cannot
reuptake dopamine from the synaptic cleft efficiently. Non-
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FIGURE 2 | Model illustrating the processes of levodopa-dopamine metabolism and uptake. (A) Normal striatum (B) Dopamine-denervated striatum. Note
that MAO-A localization is unclear. A study suggests MAO-A is mainly expressed in medium spiny neurons, rather than in axon terminals in the striatum. Serotonergic
neurons express MAO-B in their cell bodies, however, it is still unclear whether the neurons express MAO in axon terminals. OCT-3 also exists in neurons, however the
specific subtype is unknown. PMAT is illustrated at the astrocyte membrane according to one recent study (see text), although its localization is not certain yet. 3-MT,
3-methoxytyramine; 3-OMD, 3-O-methyldopa; AADC, aromatic amino acid decarboxylase; ALD.DH, aldehyde dehydrogenase; COMT, catechol-O-methyltransferase;
D2R, dopamine D2 receptor; DA, dopamine; DAT, dopamine transporter; DCI, dopa-decarboxylase inhibitor; DOPAC, dihydroxyphenylacetic acid; DOPALD,
dihydroxyphenylacetaldehyde; DR, dopamine receptor; HVA, homovanillic acid; MAO, monoamine oxidase; NET, norepinephrine transporter, noradrenaline
transporter; OCT, organic cation transporter; PMAT, plasma membrane monoamine transporter; SERT, serotonin transporter; VMAT-2, vesicular monoamine
transporter-2.
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regulated release of dopamine induces pulsatile fluctuations of
extracellular dopamine concentrations in the striatum, leading
to motor complications in advanced PD patients such as
levodopa-induced dyskinesia (Olanow and Obeso, 2000; Pavese
et al., 2006; Cheshire and Williams, 2012; Politis et al.,
2014).
Dopamine in the striatum is metabolized by monoamine
oxidase (MAO)-A,MAO-B, aldehyde dehydrogenase (ALD.DH),
and COMT into homovanillic acid (HVA; Kaakkola, 2000; Gesi
et al., 2001; Figure 1). In the striatum, MAO-A exists at the
outer membrane of mitochondria in the axon terminals of
catecholamine neurons (Westlund et al., 1993) or in medium
spiny neurons (Sader-Mazbar et al., 2013). The majority of
MAO-B is detected in astrocytes in the brain (Levitt et al.,
1982; Westlund et al., 1985; Ekblom et al., 1993; Sader-
Mazbar et al., 2013). Some MAO-B activity is detected
in medium spiny neurons (Sader-Mazbar et al., 2013) and
perikarya of serotonergic neurons (Levitt et al., 1982; Arai
et al., 1998, 2002). COMT is primarily expressed in glial
cells, and some in postsynaptic cells (Männistö and Kaakkola,
1999; Kaakkola, 2000). Soluble COMT exists in striatal glial
cells, whereas membrane-bound COMT exists in postsynaptic
neurons and non-neuronal cells (Kaakkola et al., 1987).
Dopamine is metabolized into dihydroxyphenylacetaldehyde
(DOPALD) via MAO-A or MAO-B. DOPALD is converted to
dihydroxyphenylacetic acid (DOPAC) by ALD.DH, which is
finally metabolized into HVA by COMT. COMT in the central
nervous system converts dopamine into 3-methoxytyramine (3-
MT), which is then metabolized into HVA via MAO (Männistö
and Kaakkola, 1999; Kaakkola, 2000; Figures 1, 2A,B).
Extracellular dopamine is reuptaken into neurons or glial
cells to be metabolized by MAO and COMT as described
above, or to be reused. Despite a >70% striatal DAT loss
in a PD model rat, dopamine uptake decreases only 25%,
and dopamine uptake per remaining DAT protein increases
as DAT loss approaches 99% (Chotibut et al., 2012). This
can be explained by high affinity of DAT for dopamine
and enough capacity to transport available dopamine in the
striatum, however, an alternate explanation is that transporters
other than DAT compensate for DAT loss. Recent studies
have demonstrated that serotonin transporters (SERT) and
norepinephrine transporters (NET) have a greater role in
reuptake of extracellular dopamine in the highly dopamine-
denervated striatum where DAT is also lost (Chotibut et al.,
2012). Thus, it is probable that selective serotonin reuptake
inhibitors (SSRI) and serotonin and norepinephrine reuptake
inhibitors (SNRI), which are often administered to PD
patients in clinical practice, can influence the motor effects of
levodopa.
The aim of this review is to summarize recent advances in
understanding the role of high-affinity transporters, SERT, and
NET, in reuptake of extracellular dopamine in the striatum. It
will also address low affinity and high capacity transporters,
organic cation transporter-3 (OCT-3), and plasma membrane
monoamine transporter (PMAT) in the striatum, which can
also reuptake extracellular dopamine and are gaining increasing
attention.
THE ROLE OF SEROTONIN
TRANSPORTERS IN REUPTAKE OF
DOPAMINE IN THE
DOPAMINE-DENERVATED STRIATUM
SERT has a high affinity for serotonin uptake and the
majority of these transporters exist on the axonal plasma
membranes of serotonin fibers (Zhou et al., 1998). SERT
can also transport norepinephrine and dopamine, particularly
at high dopamine concentrations (Vizi et al., 2004; Larsen
et al., 2011). In a parkinsonian model rat brain in which
DAT is absent, levodopa-derived excessive dopamine can be
taken up by serotonergic neurons via SERT (Kannari et al.,
2006). In a study using a 6-hydroxydopamine (OHDA)-lesioned
hemiparkinsonian rat and microdialysis tecnique (Kannari
et al., 2006), acute local perfusion of the SSRI fluoxetine in
the striatum increases levodopa-derived extracellular dopamine
levels. Conversely, the same research group demonstrated that
acute systemic administration of fluoxetine decreases levodopa-
derived extracellular dopamine levels in the striatum of the same
rat model (Yamato et al., 2001). They discussed that systemic
administration of fluoxetine mainly increases extracellular
serotonin at the dorsal raphe nucleus, activating 5-HT 1A
autoreceptors; this results in reduced activity of serotonergic
neurons, including those sending efferent fibers to the striatum,
and reduced release of levodopa-derived dopamine from the
serotonergic nerve terminals (Yamato et al., 2001).
Bishop et al. demonstrated that acute systemic administration
of SSRIs, paroxetine, citalopram or fluoxetine, to 6-OHDA-
lesioned hemiparkinsonian rats attenuates dyskinesia-like
behavior without reducing the anti-parkinsonian effect of
levodopa (Bishop et al., 2012). In this study, SSRIs had no effect
on apomorphine-induced abnormal involuntary movements,
suggesting that SSRIs modify the effects of levodopa-derived
dopamine. They also examined tissue dopamine content in the
dopamine-denervated striatum after levodopa and citalopram
treatment, showing no significant changes compared with
levodopa treatment. Effects of acute systemic SSRI treatment
on striatal levodopa-derived dopamine levels are different
between the study of Yamato et al. (decrease) and that of Bishop
et al. (no significant change). Yamato et al. (2001) examined
effects of SSRI on striatal extracellular dopamine after levodopa
treatment using microdialysis, which means that the changes
should reflect alteration of synaptic dopamine level. On the other
hand Bishop et al. (2012) measured tissue dopamine content,
meaning that they examined all synaptic, and stored dopamine.
The difference in determined dopamine may account for the
difference between the two reports. This discrepancy might
be also due to their 6-OHDA lesioning for the rat PD model.
Yamato et al. confirmed dopamine-denervation with a behavioral
test using apomorphine, indicating that their model rats lost
over 99% of striatal dopaminergic neurons (Tanaka et al., 1999;
Yamato et al., 2001). On the other hand, Bishop et al. did not
show any validation for the extent of dopamine-denervation after
6-OHDA lesioning in their paper (Bishop et al., 2012). Residual
dopaminergic neurons and endogenous dopamine release may
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account for relatively low impact of acute SSRI treatment on
striatal levodopa-derived dopamine content in their study. In the
other study Bishop and his colleagues have shown that repetitive
chronic systemic administration of SSRIs (3 weeks) increased
striatal dopamine concentration after levodopa treatment in
the same rat PD model (Conti et al., 2014). In this study,
prolonged SSRI treatment attenuated dyskinesia expression
and development in levodopa-primed and -naïve animals,
respectively, without interfering with motor performance. They
discussed that this anti-dyskinetic effect of SSRI is provided in
part by 5-HT 1A receptors, while maintaining levodopa’s anti-
parkinsonian efficacy by enhancing striatal dopamine levels. In
other words, it can be speculated that the chronic SSRI treatment
in this study reduced dopamine release from serotoninergic
neurons and reduced the uptake of extracellular dopamine via
SERT, resulting in reduced fluctuation of extracellular dopamine
concentration in the striatum. This might lead to relatively
continuous dopaminergic stimulation rather than pulsatile,
attenuating levodopa-induced dyskinesia although the tissue
dopamine level increased in the striatum after chronic SSRI
treatment. Thus, these studies using rodent PD model indicate
that serotonergic neurons not only release levodopa-derived
dopamine but also reuptake extracellular dopamine via SERT in
parkinsonian striatum (Figure 2B).
Clinical studies of the motor effects of SSRI treatment in PD
patients have yielded conflicting results; SSRIs have been shown
to improve (Rampello et al., 2002), worsen (Linazasoro, 2000), or
have no influence (Chung et al., 2005) over the anti-parkinsonian
efficacy of levodopa. As described above, SSRIs potentially
increase dopamine concentration in the striatum via SERT
blockade, although they may attenuate activity of serotonergic
neurons and reduce levodopa-derived dopamine release (Yamato
et al., 2001). Thus, to date no SSRI is clinically applied to treat
motor symptoms of PD. The clinical use of SSRIs and other
monoamine transporter inhibitors for PD have been recently
discussed in a comprehensive review by Huot et al. (2015). In
clinical practice, major clinical effects of SSRIs on PD motor
symptoms are not seen so frequently. Most of preclinical data
is acute administration of SSRI rather than chronic, with supra-
optimal levodopa doses that may be therapeutically irrelevant.
These may explain the discrepancy between experimental data
and clinical situations.
THE ROLE OF NOREPINEPHRINE
TRANSPORTERS IN REUPTAKE OF
DOPAMINE IN THE
DOPAMINE-DENERVATED STRIATUM
NET has affinity not only for norepinephrine but also for
dopamine (Horn, 1973; Raiteri et al., 1977). The transporter’s
affinity for dopamine is as strong as that of DAT (Gu et al.,
1994; Giros et al., 1996; Eshleman et al., 1999). While reuptake of
dopamine occurs mainly via DAT in the normal striatum (Moron
et al., 2002), in brain regions with sparse dopamine innervations,
such as the prefrontal cortex, NET is a major site for dopamine
uptake (Moron et al., 2002).
In normal striatum, norepinephrinergic neurons and NET
are sparsely expressed. However, studies suggest NET plays a
larger role in the dopamine-denervated striatum. NET expression
is increased and NET reuptakes extracellular dopamine in the
6-OHDA-lesioned parkinsonian striatum of a rat (Chotibut
et al., 2012). Acute systemic administration of desipramine (25
mg/kg), a selective NET inhibitor, increases the extracellular
dopamine concentration after levodopa treatment in the striatum
of this PD model (Arai et al., 2008). Chronic administration
of desipramine (12 mg/kg) also increases the striatal dopamine
concentration and enhances dyskinesia-like behaviors induced
by levodopa injection to this model rat (Chotibut et al.,
2014). These studies suggest that NET has a significant role
in reuptake of extracellular dopamine in the PD striatum.
However, the targeted NETs are not necessarily expressed by
norepinephrinergic neurons. In the striatum of a 6-OHDA-
lesioned hemiparkinsonian rat, NET expression increases but
norepinephrine tissue content remains the same (Chotibut et al.,
2012). Navailles et al. (2014) showed in a similar rat model that
destruction of norepinephrine fibers using N-(2-chloroethyl)-
N-ethyl-2-bromobenzylamine does not potentiate the levodopa
effect in the striatum. These results suggest that increased
NET is expressed on cells other than norepinephrinergic
neurons. The increased expression could occur on glial cells,
which also express NETs (Takeda et al., 2002; Inazu et al.,
2003). In cultured astrocytes from rat cortex, a NET blocker
inhibits uptake of dopamine and norepinephrine; the effect
was not seen with a DAT blocker, indicating dopamine
uptake is performed by NETs in astrocytes (Takeda et al.,
2002). In a parkinsonian state, the number of astrocytes
increase with dopaminergic denervation (Teismann and Schulz,
2004; Asanuma et al., 2014). Thus, increased NET activity
of dopamine transport in the dopamine-denervated striatum
may occur at astrocytes, not at norepinephrinergic neurons
(Figure 2B). Another possible source of increased NET is
tyrosine hydroxylase-positive neurons which have been shown
to increase in the striatum after dopamine-depletion (Darmopil
et al., 2008; Ünal et al., 2015). These neurons can be
spiny projection neurons (Darmopil et al., 2008) or striatal
interneurons (Ünal et al., 2015), which are considered to appear
after a compensatory phenotypic conversion of a population
of pre-existing striatal neurons. However, to our knowledge
there have been no evidence of NET expressions in these
neurons.
Conversely, there is one study in the striatum suggesting
that NETs and norepinephrinergic neurons may not be
significantly involved in reuptake of dopamine, even when
dopaminergic neurons are significantly reduced. Navailles et al.
(2014) showed in 6-OHDA-lesioned rats that the NET blockers
desipramine (10 mg/kg) and reboxetine (3 mg/kg) potentiated
the levodopa effect in the prefrontal cortex, substantia nigra
pars reticulata, and hippocampus, but not in the striatum. They
discussed that the contradictory result of Arai et al. (2008)
is because of their high dose of desipramine (25 mg/kg), in
which desipramine non-selectively binds to sites other than
NET. However, Chotibut et al. (2014) used a lower dose of
desipramine (12 mg/kg) and demonstrated a significant increase
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of levodopa-derived dopamine concentration in the dopamine-
denervated striatum. The inconsistencies between studies may be
due to residual DAT expression and activity of SERT and other
monoamine transporters in the particular experimental situation
(Figure 2B). Although it is difficult to interpret the discrepancies
among studies, it remains possible that NET plays a role in
reuptake of extracellular dopamine in the dopamine-denervated
striatum.
THE ROLE OF LOW AFFINITY
TRANSPORTERS IN THE STRIATUM:
ORGANIC CATION TRANSPORTER-3
(OCT-3) AND PLASMA MEMBRANE
MONOAMINE TRANSPORTER (PMAT)
DAT, NET, and SERT are high-affinity transporters for dopamine,
norepinephrine, and serotonin, respectively, all of which belong
to the solute carrier (SLC) 6A family. They are the primary
targets for drugs used to treat depression and other psychiatric
disorders and may transport some neurotoxins in patients with
drug addiction and animal models of the diseases (Giros and
Caron, 1993; Torres et al., 2003). Other than these high-affinity
amine transporters, additional transporters for biogenic amines
in the brain have been identified, such as OCT (Gründemann
et al., 1998; Eisenhofer, 2001; Vialou et al., 2004; Amphoux
et al., 2006; Koepsell et al., 2007) and PMAT (Engel et al.,
2004; Engel and Wang, 2005), which have low affinity but
high capacity for monoamine transport. These low affinity
transporters could become more important in the clearance
of monoamines when high-affinity transporters do not work
normally (Hensler et al., 2013), such as in PDwhen dopaminergic
neurons and DAT are significantly reduced, and levodopa-
derived dopamine is excessively released in the extracellular
space.
OCT-3
OCT is a member of the SLC superfamily, the organic
cation/anion/zwitterion (SLC 22) family of transporters.
Decynium-22 (D-22) can block OCT. OCT-1 and OCT-2 are
mainly expressed in the liver and kidney, respectively (Lee
et al., 2009). OCT-3 is expressed in various organs including
the brain (Lee et al., 2009). In the central nervous system,
OCT-3 is detected in glial cells and neurons in rodents (Vialou
et al., 2004; Cui et al., 2009). Astrocytes in substantia nigra
and striatum adjacent to soma and terminals of midbrain
dopaminergic neurons express OCT-3, whereas those in
cerebellum, hippocampus and cortex do not express OCT-3 (Cui
et al., 2009). OCT-3 expression has also been reported in cultured
human astrocytes (Yoshikawa et al., 2013). It is not clear which
type of neurons express OCT-3.
OCT-3 depletion in mice increases extracellular dopamine
elevation after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) treatment. The same mouse model also shows
elevated extracellular dopamine concentration after high-
dose methamphetamine treatment, but not after low-dose
treatment (Cui et al., 2009). These results suggest that OCT-3
has a role in the removal of excess extracellular dopamine
when dopamine concentration is high and has overcome the
capacity of DAT. OCT-3 depletion also hampered the release
of toxic organic cation 1-methyl-4-phenylpyridinium from
astrocytes and protected against MPTP-induced dopaminergic
neurodegeneration in mice (Cui et al., 2009). In 6-OHDA-
lesioned parkinsonian rats, OCT-3 inhibitor D-22 increases
extracellular dopamine concentrations (Sader-Mazbar et al.,
2013), although D-22 also inhibits PMAT.
These studies suggest OCT-3 plays a role in the regulation of
dopamine concentration in the parkinsonian striatum and could
be a target for PD treatment.
PMAT
PMAT is a member of the SLC 29, equilibrative nucleoside
transporter family. PMAT is also one of the D-22 sensitive
transporters, which can be blocked by D-22, similar to OCT-3. In
mice, PMAT is expressed exclusively in neurons, not in astrocytes
(Dahlin et al., 2007). It is still unclear which type of neurons
expresses PMAT. One study showed that PMAT is distributed
in various neuron subtypes throughout the brain, including
cholinergic interneurons in the striatum (Vialou et al., 2007).
However, another study demonstrated that PMAT is expressed
in cultured human astrocytes (Yoshikawa et al., 2013). Thus, the
localization of PMAT remains unclear.
As mentioned in the preceding subsection, Sader-Mazbar
et al. (2013) demonstrated that in 6-OHDA-lesioned rats, D-
22 treatment increases extracellular dopamine in the striatum.
They emphasized the inhibition of OCT-3, but D-22 can also
inhibit PMAT. The result might partly be due to PMAT inhibition
leading to reduced reuptake of dopamine via PMAT.
CLOSING REMARKS
We reviewed levodopa-dopamine metabolism and pathways in
which extracellular dopamine is reuptaken in the dopamine-
denervated striatum. Most of the studies addressed were
performed using rodent models of PD induced with neurotoxin.
Further studies are needed to expand the discussion in this review
to higher species.
To date, various drugs that modify dopamine metabolism
and uptake, especially monoamine transporter inhibitors, have
been investigated for treatment of PD motor and non-motor
symptoms. Since the recent comprehensive review by Huot
et al. (2015), new studies have been published. For example,
Conti et al. examined the effect of clomipramine, amitriptyline,
and desipramine (Conti et al., 2016). We also recently showed
the effect of duloxetine, an SNRI, on motor symptoms of
PD (Nishijima et al., 2016). These studies suggest that all
SSRI, SNRI, and other monoamine transporter inhibitors
potentially influence dopamine metabolism and clearance in
the striatum of advanced PD patients. Thus, when these
drugs are administered to PD patients for depression, pain
or other non-motor symptoms, it is important to keep
in mind that the drug may modify dopamine metabolism
Frontiers in Neuroscience | www.frontiersin.org 6 December 2016 | Volume 10 | Article 575
Nishijima and Tomiyama Dopamine Uptake in Parkinsonian Striatum
and uptake, leading to changes in motor symptoms and
motor complications in PD patients. Furthermore, low affinity
monoamine transporters such as OCT-3 and PMAT may be new
targets to modify dopamine metabolism for PD treatment in
future studies.
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